Join STAT to explore how the biopharma industry is advancing outcome-based multimodal therapeutics on Nov. 22.

In this Thought Leader article., Ian Johnston from Cytiva discusses challenges related to process development, scaling technology, regulatory approvals, and GMP guidelines.

The US FDA has granted orphan drug designation (ODD) to Modalis Therapeutics’ MDL-101, aimed at treating LAMA2-CMD.

Dyno has formed a new research partnership with Roche on the development of AAV gene therapy vectors for neurological ...

How do you whittle 35 years of headlining business news down to a couple thousand words and a few pages? You don't. But here, ...

Q3 2024 Earnings Call Transcript October 22, 2024 Danaher Corporation beats earnings expectations. Reported EPS is $1.71, ...

We may also describe certain products and devices which have applications ... we're increasingly excited about the long term opportunities ahead for Cytiva's leading bioprocessing franchise.

Google Shopping is rolling out a personalized feed that shows you a stream of products you might like. The new feature, which is coming to mobile and desktop devices, shows up when you head to ...

This valuable study uses robust time-dependent microscopy assays to show that during HIV-1 infection, the viral accessory protein Vif causes cell cycle arrest during metaphase and not G2/M as ...

A central question in adult stem cell biology is elucidating the signaling pathways regulating their dynamics and function in diverse physiological and age-related contexts. Muscle stem cells in ...